**INTRODUCTION**

**Review question / Objective:** To investigate the efficacy and safety of bone marrow mononuclear cell (BMMNCs) transplantation treatment of ischemic stroke (IS).

**Condition being studied:** BMMNCs transplantation therapy is a potential treatment for IS. Several RCTs related to BMMNCs transplantation for IS have been published, while the results are inconclusive.

**METHODS**

**Participant or population:** IS, aged over 18.

**Intervention:** BMMNCs transplantation treatment with conventional drug treatment.
Comparator: Conventional drug treatment or with a sham bone marrow harvest and a sham infusion procedure.

Study designs to be included: RCT.

Eligibility criteria: Review, letter, comment case reports or case series.

Information sources: MEDLINE, Embase, the Cochrane Library, and clinicalTrials.gov

Main outcome(s): mRS score and NIHSS score.

Quality assessment / Risk of bias analysis: The risk of bias were assessed with Cochrane Collaboration tool.

Strategy of data synthesis: Data was analysed by Review Manager 5.3. Risk ratio was analyzed with 95% confidence intervals. P ≤0.05 was statistically significant.

Subgroup analysis: The dosage and route of administration of BMMSCs.

Sensitivity analysis: Cochrane’s Q test and I² were used to explore heterogeneity.

Country(ies) involved: China.

Keywords: Ischemic stroke, randomized control trial, stem cells, stem cell therapy.

Contributions of each author:
Author 1 - Yanbing Tang.
Email: tangyb02@163.com
Author 2 - Zilan Wang.
Author 3 - Haiying Teng.
Author 4 - Huiru Chen.
Author 5 - Jiaye Lu.
Author 6 - Zhouqing Chen.
Author 7 - Zhong Wang.